Abstract
Introduction In large brain metastases (BM) with a diameter of more than 2aEuro ($) over bar cm there is an increased risk of radionecrosis (RN) with standard stereotactic radiosurgery (SRS) dose prescription, while the normal tissue constraint is exceeded. The tumor control probability (TCP) with a single dose of 15Gy is only 42%. This in silico study tests the hypothesis that isotoxic dose prescription (IDP) can increase the therapeutic ratio (TCP/Risk of RN) of SRS in large BM. Materials and methods A treatment-planning study with 8 perfectly spherical and 46 clinically realistic gross tumor volumes (GTV) was conducted. The effects of GTV size (0.5-4cm diameter), set-up margins (0, 1, and 2mm), and beam arrangements (coplanar vs non-coplanar) on the predicted TCP using IDP were assessed. For single-, three-, and five-fraction IDP dose-volume constraints of V-12Gy=10cm(3), V-19.2Gy=10cm(3), and a V-20Gy=20cm(3), respectively, were used to maintain a low risk of radionecrosis. Results In BM of 4cm in diameter, the maximum achievable single-fraction IDP dose was 14Gy compared to 15Gy for standard SRS dose prescription, with respective TCPs of 32 and 42%. Fractionated SRS with IDP was needed to improve the TCP. For three- and five-fraction IDP, a maximum predicted TCP of 55 and 68% was achieved respectively (non-coplanar beams and a 1mm GTV-PTV margin). Conclusions Using three-fraction or five-fraction IDP the predicted TCP can be increased safely to 55 and 68%, respectively, in large BM with a diameter of 4cm with a low risk of RN. Using IDP, the therapeutic ratio of SRS in large BM can be increased compared to current SRS dose prescription.
Original language | English |
---|---|
Pages (from-to) | 560-569 |
Number of pages | 10 |
Journal | Strahlentherapie Und onkologie |
Volume | 194 |
Issue number | 6 |
DOIs | |
Publication status | Published - 1 Jun 2018 |
Keywords
- Radiotherapy
- Stereotactic
- Dose prescription
- Normal tissue tolerance
- Large brain metastases
- RADIATION-ONCOLOGY
- RADIOTHERAPY
- HYPOFRACTIONATION
- TRIAL
- TOXICITY
- EFFICACY
- PROTOCOL
- TUMORS
- NSCLC